* BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66(®) cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known ...

Vivalis strengthens its management team with the appointment of Philippe Rousseau, as Chief Financial Officer VIVALIS (PARIS: VLS), a biopharmaceutical company that provides the pharmaceutical ...

Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...

NANTES, FRANCE--(Marketwire - June 8, 2010) - VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY ...

PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...

On 16 December 2012, Vivalis SA and Intercell AG have announced their intention to merge and form Valneva SE (“Valneva”). The merger is progressing well, in line with the timeline communicated at time ...

Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...

LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...

FRENCH biotech firm Vivalis and its British partner GlaxoSmithKline have won US clearance to begin testing for the first time on humans flu vaccines that were produced using Vivalis’s technology.

Vivalis shareholders will own 55% of Valneva, with Intercell’s shares being converted at a 39% premium to the pre-deal share prices. An extra 8.6m shares will be issued to former Intercell ...

ATLANTA and NANTES, France, July 22 GeoVax Labs,Inc. (OTC Bulletin Board: GOVX), an Atlanta based, biopharmaceutical companydeveloping human vaccines for diseases caused by HIV-1 (Human ...

Valneva SE (Valneva) has announced the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become ...